Key Developments: Halozyme Therapeutics Inc (HALO.A)

HALO.A on American Stock Exchange

15.78USD
27 Apr 2015
Change (% chg)

-- (--)
Prev Close
$15.78
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
0
52-wk High
$17.25
52-wk Low
$7.58

Search Stocks

Latest Key Developments (Source: Significant Developments)

Halozyme Therapeutics Inc raises FY 2015 revenue outlook
Monday, 10 Aug 2015 04:05pm EDT 

Halozyme Therapeutics Inc:Revises FY 2015 net revenue to be in the range of $110 to $115 million, from a prior range of $85 to $95 million.FY 2015 revenue of $96 million - Thomson Reuters I/B/E/S.  Full Article

Halozyme Therapeutics Inc plans for CFO transition, names Laurie Stelzer CFO
Friday, 5 Jun 2015 09:00am EDT 

Halozyme Therapeutics Inc:Announces plans for CFO transition, names laurie stelzer CFO.Says chief financial officer david ramsay will retire this summer.Says stelzer will assume CFO duties on June 15 and will work with ramsay through transition period.  Full Article

Halozyme Therapeutics Inc Enters into global collaboration and licensing agreement with AbbVie Inc
Wednesday, 3 Jun 2015 08:30am EDT 

Halozyme Therapeutics Inc:Enters into global collaboration and licensing agreement with AbbVie Inc.Says Halozyme will receive an initial $23 million payment.Says payments are subject to abbvie's achievement of specified development, regulatory and sales-based milestones.Says AbbVie will pay Halozyme tiered royalties if products under the collaboration are commercialized.Initial payment followed by milestone payments totaling about $130 million for each of up to nine collaboration targets.  Full Article

Halozyme Therapeutics, Inc and Ventana Enter Into Global Agreement To Collaboratively Develop Companion Diagnostic For Cancer Treatment
Wednesday, 27 May 2015 08:30am EDT 

Halozyme Therapeutics, Inc:Says collaborate on the development of, and for Ventana to ultimately commercialize, a companion diagnostic assay for use with Halozyme's investigational new drug, PEGPH20.Ventana will develop an in vitro diagnostic (IVD), under design control, using Halozyme's proprietary HA binding protein, with the intent of submitting it for regulatory approval in the United States, Europe and other countries.  Full Article

Halozyme Therapeutics Inc reiterates FY 2015 revenues guidance
Monday, 11 May 2015 04:05pm EDT 

Halozyme Therapeutics Inc:Reiterates its previously disclosed FY 2015 guidance.Expects FY 2015 net revenues to be in the range of $85 million to $95 million.FY 2015 revenue of $93 million - Thomson Reuters I/B/E/S.  Full Article

Halozyme Therapeutics Inc reaffirms FY 2015 revenue outlook
Monday, 2 Mar 2015 04:15pm EST 

Halozyme Therapeutics Inc:Expects FY 2015 net revenues to be in the range of $85 - $95 mln.  Full Article

Halozyme Therapeutics Inc gives FY 2015 revenue guidance below analysts' estimates - Conference Call
Wednesday, 7 Jan 2015 10:00am EST 

Halozyme Therapeutics Inc:Estimates FY 2015 net revenues in the range of $85 million to $95 million.FY 2015 revenue of $98 million - Thomson Reuters I/B/E/S.  Full Article

Halozyme Therapeutics Inc receives FDA approval for additional manufacturing facilities for Hylenex Recombinant
Monday, 20 Oct 2014 08:29am EDT 

Halozyme Therapeutics Inc:That the U.S. Food and Drug Administration (FDA) has approved new contract manufacturing facilities used in the production of Hylenex recombinant (hyaluronidase human injection).The FDA approved use of Cook Pharmica manufacturing facility in Bloomington, Indiana for the production of bulk rHuPH20, active ingredient used in Hylenex, and Patheon facility in Greenville, North Carolina, for production of finished Hylenex product.  Full Article

Halozyme Therapeutics receives orphan drug designation for PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer
Friday, 3 Oct 2014 07:45am EDT 

Halozyme Therapeutics Inc:Announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for PEGylated recombinant human hyaluronidase (PEGPH20) for the treatment of pancreatic cancer.Says the FDA Office of Orphan Products Development (OOPD) mission is to advance the evaluation and development of products (drugs, biologics, devices, or medical foods) that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions.  Full Article

Halozyme Therapeutics Inc consistent 1 trial of hylenex recombinant meets primary endpoint
Monday, 31 Mar 2014 08:00am EDT 

Halozyme Therapeutics Inc:Says primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial.The trial is evaluating Hylenex recombinant and a new formulation of Hylenex currently under U.S Food and Drug Administration review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes.With respect to secondary endpoints, the rate of overall hypoglycemic events (serum glucose of 70mg/dL) in the combined treatment groups was reduced by 12 pct (p=.08) compared to the control group.  Full Article

Search Stocks